Torthaí cuardaigh - Sive, Jonathan

Transcriptional network control of normal and leukaemic haematopoiesis de réir Sive, Jonathan I., Göttgens, Berthold

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry de réir Sayar, Zara, Weatherill, Anna, Keddie, Stephen, Sive, Jonathan, Lunn, Michael P., Thomas, Mari, D’Sa, Shirley

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... de réir Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Outcomes In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC UKALL XII/ECOG2993 Trial de réir Sive, Jonathan I., Buck, Georgina, Fielding, Adele, Lazarus, Hillard M., Litzow, Mark R., Luger, Selina, Marks, David I., McMillan, Andrew, Moorman, Anthony V., Richards, Susan M., Rowe, Jacob M., Tallman, Martin S., Goldstone, Anthony H.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma de réir Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial de réir Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study de réir Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy de réir Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines de réir Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina, Dowling, Emma, Correia, Nuno, Lecat, Catherine, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee, Xu, Ke

Faigh an téacs iomlán Faigh an téacs iomlán

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease fac... de réir Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J., Dowling, Emma, Correia, Nuno, Lecat, Catherine S. Y., McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee L., Xu, Ke

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors de réir Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J, Dowling, Emma, Correia, Nuno, Lecat, Catherine SY, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh D., Popat, Rakesh, Rabin, Neil K, Nastouli, Eleni, Yong, Kwee, Xu, Ke

Faigh an téacs iomlán Faigh an téacs iomlán

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature de réir Chapman, Michael A., Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Lach, Anna, Abbasian, Mahnaz, Popat, Rakesh, Cavenagh, Jamie D., Oakervee, Heather, Streetly, Matthew J., Schey, Stephen, Koh, Mickey, Willis, Fenella, Virchis, Andres E., Crowe, Josephine, Quinn, Michael F., Cook, Gordon, Crawley, Charles R., Pratt, Guy, Cook, Mark, Braganza, Nivette, Adedayo, Toyin, Smith, Paul, Clifton-Hadley, Laura, Owen, Roger G., Sonneveld, Pieter, Keats, Jonathan J., Herrero, Javier, Yong, Kwee

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán